These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 10090611)

  • 21. Alloreactive cytotoxic T-lymphocyte-defined HLA-B7 subtypes differ in peptide antigen presentation.
    Smith KD; Epperson DF; Lutz CT
    Immunogenetics; 1996; 43(1-2):27-37. PubMed ID: 8537119
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytotoxic T lymphocyte response and viral load in hepatitis C virus infection.
    Hiroishi K; Kita H; Kojima M; Okamoto H; Moriyama T; Kaneko T; Ishikawa T; Ohnishi S; Aikawa T; Tanaka N; Yazaki Y; Mitamura K; Imawari M
    Hepatology; 1997 Mar; 25(3):705-12. PubMed ID: 9049223
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HLA restriction and T-cell-receptor V beta gene expression of cytotoxic T lymphocytes reactive with human squamous-cell carcinoma of the head and neck.
    Yasumura S; Weidmann E; Hirabayashi H; Johnson JT; Herberman RB; Whiteside TL
    Int J Cancer; 1994 May; 57(3):297-305. PubMed ID: 8168988
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The immunogenicity of a viral cytotoxic T cell epitope is controlled by its MHC-bound conformation.
    Tynan FE; Elhassen D; Purcell AW; Burrows JM; Borg NA; Miles JJ; Williamson NA; Green KJ; Tellam J; Kjer-Nielsen L; McCluskey J; Rossjohn J; Burrows SR
    J Exp Med; 2005 Nov; 202(9):1249-60. PubMed ID: 16275762
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inefficient exogenous loading of a tapasin-dependent peptide onto HLA-B*44:02 can be improved by acid treatment or fixation of target cells.
    Stroobant V; Demotte N; Luiten RM; Leonhardt RM; Cresswell P; Bonehill A; Michaux A; Ma W; Mulder A; Van den Eynde BJ; van der Bruggen P; Vigneron N
    Eur J Immunol; 2012 Jun; 42(6):1417-28. PubMed ID: 22678898
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Simultaneous prediction of binding capacity for multiple molecules of the HLA B44 supertype.
    Sidney J; Southwood S; Pasquetto V; Sette A
    J Immunol; 2003 Dec; 171(11):5964-74. PubMed ID: 14634108
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor associated antigens in human renal cell carcinoma: MHC restricted recognition by cytotoxic T lymphocytes.
    Bernhard H; Jäger E; Maeurer MJ; Meyer zum Büschenfelde KH; Knuth A
    Tissue Antigens; 1996 Jul; 48(1):22-31. PubMed ID: 8864171
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polymorphism of human minor histocompatibility antigens: T cell recognition of human minor histocompatibility peptides presented by HLA-B35 subtype molecules.
    Beck Y; Satz L; Takamiya Y; Nakayama S; Ling L; Ishikawa Y; Nagao T; Uchida H; Tokunaga K; Müller C
    J Exp Med; 1995 Jun; 181(6):2037-48. PubMed ID: 7759996
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular analysis of presentation by HLA-A2.1 of a promiscuously binding V3 loop peptide from the HIV-envelope protein to human cytotoxic T lymphocytes.
    Alexander-Miller MA; Parker KC; Tsukui T; Pendleton CD; Coligan JE; Berzofsky JA
    Int Immunol; 1996 May; 8(5):641-9. PubMed ID: 8671651
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Wild-type p53 epitope naturally processed and presented by an HLA-B haplotype on human breast carcinoma cells.
    Papadopoulos KP; Hesdorffer CS; Suciu-Foca N; Hibshoosh H; Harris PE
    Clin Cancer Res; 1999 Aug; 5(8):2089-93. PubMed ID: 10473091
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Constraints within major histocompatibility complex class I restricted peptides: presentation and consequences for T-cell recognition.
    Theodossis A; Guillonneau C; Welland A; Ely LK; Clements CS; Williamson NA; Webb AI; Wilce JA; Mulder RJ; Dunstone MA; Doherty PC; McCluskey J; Purcell AW; Turner SJ; Rossjohn J
    Proc Natl Acad Sci U S A; 2010 Mar; 107(12):5534-9. PubMed ID: 20212169
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of a dominant self-ligand bound to three HLA B44 alleles and the preliminary crystallographic analysis of recombinant forms of each complex.
    Macdonald W; Williams DS; Clements CS; Gorman JJ; Kjer-Nielsen L; Brooks AG; McCluskey J; Rossjohn J; Purcell AW
    FEBS Lett; 2002 Sep; 527(1-3):27-32. PubMed ID: 12220628
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cross-reactive memory T cells for Epstein-Barr virus augment the alloresponse to common human leukocyte antigens: degenerate recognition of major histocompatibility complex-bound peptide by T cells and its role in alloreactivity.
    Burrows SR; Silins SL; Khanna R; Burrows JM; Rischmueller M; McCluskey J; Moss DJ
    Eur J Immunol; 1997 Jul; 27(7):1726-36. PubMed ID: 9247584
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recognition of breast cancer-associated peptides by tumor-reactive, HLA-class I restricted allogeneic cytotoxic T lymphocytes.
    Nguyen T; Naziruddin B; Dintzis S; Doherty GM; Mohanakumar T
    Int J Cancer; 1999 May; 81(4):607-15. PubMed ID: 10225452
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alloreactive cytotoxic T lymphocytes focus on specific major histocompatibility complex-bound peptides.
    Smith KD; Huczko E; Engelhard VH; Li YY; Lutz CT
    Transplantation; 1997 Jul; 64(2):351-9. PubMed ID: 9256200
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Single T cell receptor-mediated recognition of an identical HIV-derived peptide presented by multiple HLA class I molecules.
    Ueno T; Tomiyama H; Takiguchi M
    J Immunol; 2002 Nov; 169(9):4961-9. PubMed ID: 12391209
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A cyclophilin B gene encodes antigenic epitopes recognized by HLA-A24-restricted and tumor-specific CTLs.
    Gomi S; Nakao M; Niiya F; Imamura Y; Kawano K; Nishizaka S; Hayashi A; Sobao Y; Oizumi K; Itoh K
    J Immunol; 1999 Nov; 163(9):4994-5004. PubMed ID: 10528204
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A human minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia.
    Dolstra H; Fredrix H; Maas F; Coulie PG; Brasseur F; Mensink E; Adema GJ; de Witte TM; Figdor CG; van de Wiel-van Kemenade E
    J Exp Med; 1999 Jan; 189(2):301-8. PubMed ID: 9892612
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A MAGE-A1 peptide presented to cytolytic T lymphocytes by both HLA-B35 and HLA-A1 molecules.
    Luiten RM; Demotte N; Tine J; van der Bruggen P
    Tissue Antigens; 2000 Jul; 56(1):77-81. PubMed ID: 10958359
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HLA-A2 subtypes are functionally distinct in peptide binding and presentation.
    Barouch D; Friede T; Stevanović S; Tussey L; Smith K; Rowland-Jones S; Braud V; McMichael A; Rammensee HG
    J Exp Med; 1995 Dec; 182(6):1847-56. PubMed ID: 7500030
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.